BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...

On Wednesday, Nuvation Bio Inc (NUVB) stock saw a decline, ending the day at $3.01 which represents a decrease of $-0.24 or -7.38% from the prior close of $3.25. The stock opened at $3.32 and touched ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand ...

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...